<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport to Support World-Leading Life Science Company's Custom Development and Biologics Manufacturing Business

August 2, 2016

Read More

Cryoport to Report First Quarter Fiscal 2017 Financial Results on August 15th

August 1, 2016

Read More

Cryoport Reminds All Interested Parties That Today is the Final Day to Become a Rights Offering Record Date Holder

May 25, 2016

Read More

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease

May 23, 2016

Read More

Cryoport Signs Strategic Partnership Deal With Worthington Industries

April 13, 2016

Irvine, CA – April 13, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, announced today that it has entered into a strategic partnership with Worthington Industries (NYSE: WOR), maker of cryogenic storage vessels and equipment. Through this partnership, Worthington’s CryoScience by Taylor Wharton business will design and manufacture biostorage and logistics equipment for use in Cryoport’s life sciences cryogenic logistics solutions.

Read More

Cryoport Announces Global Temperature Controlled Logistics Consulting Services

April 11, 2016

New consulting and advisory division extends Cryoport's expertise in cryogenic logistics to the life sciences industry

- - -

Irvine, CA – April 11, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, announced the launch of a new Temperature Controlled Logistics Consulting Division to assist life sciences companies in developing strategies for global cold chain logistics management and contingency options to protect their valuable, and often irreplaceable, biological commodities.

Read More

Cryoport Chosen to Provide Cold Chain Logistics Support to ProteoGenex

April 4, 2016

Irvine, Calif., April 4, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, today announced it is providing cryogenic logistics solutions that support ProteoGenex, Inc.'s (“ProteoGenex”) shipping of biological specimens, including PBMCs, BMMCs, frozen tissue, OCT-embedded tissue, blood serum, blood plasma, whole blood, RNA/DNA, and other bio-fluids.  

Read More

UPS Adds Cryogenic Shipping to Its Temperature-Sensitive Portfolio In Europe

March 15, 2016

UPS Temperature True® Cryo keeps products frozen at -150° C, and provides monitoring, intervention and financial risk mitigation


BRUSSELS, March 15, 2016 -- UPS (NYSE: UPS) announced the launch of UPS Temperature True® Cryo in Europe, providing healthcare customers access to end-to-end product protection and capability to ship parcels in a cryogenic environment. The service includes real-time tracking and intervention, which, when combined with UPS’s risk mitigation solutions and global network of control towers, will provide complete visibility for shipments at every stage of the supply chain journey.

Read More

Cryoport Supports ImmunoCellular Therapeutics’ 120-Site Phase III Clinical Trial With Cold Chain Logistics

March 3, 2016

Irvine, CA – March 3, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company, today announced that it will be supporting the cryogenic logistics requirements of ImmunoCellular Therapeutics’ (NYSE MKT: IMUC) (“ImmunoCellular”) registrational Phase III glioblastoma clinical trial across 120 sites in North America and Europe. This clinical trial is designed to evaluate the safety and efficacy of ImmunoCellular’s lead product candidate ICT-107, a patient-derived dendritic cell-based immunotherapy.  

Read More

Cryoport Supports Perseus PCI in Melanoma and Ovarian Cancer Clinical Trials

February 16, 2016

- - -

Cryoport’s advanced cold chain logistics solutions are increasingly crucial to enabling life sciences development

Irvine, CA – February 16, 2016 — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the world’s leading cryogenic logistics company, announced today that it will manage the cryogenic shipping of solid tumor samples and vaccine for Perseus PCI’s (“Perseus”) melanoma and ovarian cancer clinical trials.

Read More